Category: Markets
Published: 2026-06-22T16:36:54.000Z
Arrowhead Pharmaceuticals has received marketing authorization from the European Commission (EC) for REDEMPLO (plozasiran) to treat Familial Chylomicronemia Syndrome (FCS) in adults. This is the first and only siRNA medicine authorized by the EC for FCS that does not require genetic confirmation, addressing a significant unmet medical need. The approval is based on positive Phase 3 PALISADE study data, showing REDEMPLO reduced triglycerides by 80% and acute pancreatitis incidence by 83%.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.